Proposal for the Best Pharmacovigilance Plan in Japan by comparing Japan Postmarketing Studies to the U.S. Postmarketing Requirements:
10.3820/jjpe.17.55
- VernacularTitle:米国におけるPostmarketing Requirementsと日本における市販後の研究に関する比較と提言
- Author:
Akira KOKAN
;
Yasuhiko KAI
;
Shigeru KAGEYAMA
;
Kiyoshi KUBOTA
;
Kiichiro TSUTANI
;
Toshimichi NISHI
;
Rei MAEDA
;
Mikio MASADA
;
Kou MIYAKAWA
- Publication Type:Journal Article
- Keywords:
pharmacovigilance plan;
Japan postmarketing study;
postmarketing requirement;
therapeutic risk management plan
- From:Japanese Journal of Pharmacoepidemiology
2012;17(1):55-66
- CountryJapan
- Language:Japanese
-
Abstract:
Objective: To propose the best pharmacovigilance plan in Japan by comparing post marketing safety studies in Japan and the U.S.
Method: Among all of the newly approved medicines in Japan in 2010, 12 marketed products in the U. S. are selected. First, to examine the U. S. system, post-marketing safety concerns over those drugs at the time of approval in the U. S. were collected as well as its postmarketing requirements (PMR) which are studies or clinical trials that sponsors are required to conduct under one or more statutes of regulations. Then, the same drugsʼ safety issues discussed as special cautions listed during the approval process in Japan and the corresponding postmarketing safety studies were reviewed.
Result: Both countries have many safety concerns in common, however, in Japan, ongoing studies are only conventional studies, such as post-marketing surveillance studies or all-cases studies, while the U. S. conducts studies to meet each individual requirement need. Ideal post-marketing safety study designs proposed by the task force, seemed beyond sponsors capabilities, particularly with regard to conduct studies with control group, and require involvement of academia external research organizations, or establishment of the national registry system for cancer and other major diseases.
Conclusion: In Japan, Risk Management Plan (RMP) will soon be implemented in 2013, and that is expected to secure patientsʼ safety by the scientific pharmacovigilance plan with the international standard. It is an urgent task to discuss what plan is feasible in Japan and how to make the corporation of industry-government-academia a reality. (Jpn J Pharmacoepidemiol 2012; 17 (1): 55-66)
